Skip to main content
. Author manuscript; available in PMC: 2011 Oct 25.
Published in final edited form as: Clin Exp Metastasis. 2009 Mar 11;26(5):403–414. doi: 10.1007/s10585-009-9238-y

Figure 7. Monitoring the effects of AZD2171 on brain metastasis tumor bed volume.

Figure 7

a. T2 weighted images (left 4 panels) and rCBV maps (right four panels) of representative mice from the control, vehicle-treated group (four upper panels) and the AZD2171 treatment group (four lower panels). These images show metastatic lesions from morphology scans (yellow arrowheads) and corresponding blood volume pre- and post treatment. b. CD31 staining in a representative brain metastasis from an untreated or a mouse treated with AZD2171 for seven days; (scale bar=500 μm for un-cropped sections, scale bar=50 μm for the cropped sections). c. rCBV map of two small brain metastases in a mouse before and after seven days of AZD2171 treatment (black arrowheads). d. The fold change of the rCBV in brain metastases relative to the contra-lateral normal brain area in untreated and AZD2171-treated mice.